Chester County News and Community Website
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced detailed results from its pivotal Phase 3 Launch-HTN trial, showcasing the efficacy and safety of lorundrostat for patients with uncontrolled …
Mineralys Therapeutics Reveals Promising Phase 3 Results for Hypertension Drug Lorundrostat Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced that the findings from its pivotal Phase 3 Launch-HTN trial on lorundrostat, a novel medication targeting uncontrolled hypertension (uHTN) and …
Mineralys Therapeutics to Present Phase 3 Data on Lorundrostat at European Hypertension Meeting Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has reported its financial results for the first quarter ended March 31, 2025, alongside major updates on its pivotal clinical trials and …
Mineralys Therapeutics Announces Q1 2025 Financial Results and Achievements Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced that its management team will participate in the prestigious Bank of America Securities 2025 Health Care Conference. The event, which …
Mineralys Therapeutics to Present at Bank of America Health Care Conference Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced the publication of groundbreaking Phase 2 trial results for its medication lorundrostat in the New England Journal of Medicine (NEJM). The …
Mineralys Therapeutics Publishes Pivotal Hypertension Trial Results in NEJM Read More RADNOR, PA — Mineralys Therapeutics, Inc. (NASDAQ: MLYS) has announced an upcoming conference call and webinar to highlight the latest findings from its pivotal Advance-HTN and Launch-HTN clinical trials. The event …
Mineralys Therapeutics to Host Webinar on Lorundsrostat and Hypertension Treatment Progress Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced that its Phase 2 Advance-HTN trial data will be presented during a late-breaking clinical trials session at the American College of …
Mineralys Therapeutics to Present Phase 2 Advance-HTN Trial Data at ACC.25 Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced positive topline results from its pivotal Launch-HTN Phase 3 and Advance-HTN Phase 2 trials evaluating lorundrostat for the treatment of uncontrolled …
Mineralys Reports Positive Results for Hypertension Drug Lorundrostat Read More RADNOR, PA — Mineralys Therapeutics, Inc. (NASDAQ: MLYS) has scheduled a conference call and webinar on Monday, March 10, 2025, at 8:00 a.m. ET to present topline results from its …
Mineralys Therapeutics to Announce Pivotal Trial Results for Lorundrostat Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) reported its financial results for the fourth quarter and full year ending December 31, 2024, while sharing significant updates on the development of …
Mineralys Therapeutics Delivers Financial Update and Advances Pipeline for Lorundrostat Read More